Journal of global antimicrobial resistance · 2018
KPC-producing Klebsiella pneumoniae gut decolonisation following ceftazidime/avibactam-based combination therapy: A retrospective observational study.
СтатьяМногоцентровое исследованиеНаблюдательное исследованиеПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Bassetti Matteo, Carannante Novella, Pallotto Carlo, Righi Elda, Di Caprio Giovanni, Bernardo Mariano, Sodano Giuseppe, Mallardo Enza, Francisci Daniela, Sartor Assunta, Graziano Elena, Tascini Carlo
Аннотация
OBJECTIVES: KPC-producing Klebsiella pneumoniae (KPC-Kp) gut colonisation is a major risk factor for developing systemic infection. Ceftazidime/avibactam (CAZ/AVI) may have a role as decolonisation therapy in special situations.
METHODS: This was a retrospective, observational, multicentre study. The KPC-Kp gut decolonisation rate of CAZ/AVI-based therapy (Group A) was compared with other antimicrobial regimens (Group B) in patients with KPC-Kp infection.
RESULTS: Among 12 patients in Group A, 11 (91.7%) achieved gut decolonisation. None of the 24 patients of Group B were decolonised.
CONCLUSION: CAZ/AVI-based therapy could be useful in KPC-Kp gut decolonisation in high-risk patients.
METHODS: This was a retrospective, observational, multicentre study. The KPC-Kp gut decolonisation rate of CAZ/AVI-based therapy (Group A) was compared with other antimicrobial regimens (Group B) in patients with KPC-Kp infection.
RESULTS: Among 12 patients in Group A, 11 (91.7%) achieved gut decolonisation. None of the 24 patients of Group B were decolonised.
CONCLUSION: CAZ/AVI-based therapy could be useful in KPC-Kp gut decolonisation in high-risk patients.